98%
921
2 minutes
20
Background: People who are homeless or vulnerably housed face significant health inequities and yet are rarely involved in health and social care research as participants, public contributors or co-researchers. The I Am More Than… project was developed to address this lack of inclusion by working in partnership with community organisations and individuals with lived experiences of being homeless or vulnerably housed.
Objective: To co-design a flexible and inclusive approach for public and community involvement in research (sometimes referred to as public and patient involvement or PPI).
Methods: The project drew on a range of co-production and participatory research strategies, with input from various stakeholders, to identify and address enablers and barriers to participation. Community researchers with lived experience of homelessness or being vulnerably housed were central to all stages of the project, including the co-design of strategies to engage people through conversations, interviews, creative outputs and stakeholder events.
Findings: We identified core principles for inclusive public and community involvement in research. including the need to: develop relationships first and tasks second; gain a deep understanding of communities and their priorities; harness lived experience expertise; however someone may choose to share it; go at the pace of trust; and work in partnership with voluntary and community sector organisations who are embedded in their communities.
Conclusion: Developing a flexible and inclusive approach to public and community involvement in research required shifting from a transactional approach to a relational approach. The project demonstrated the importance of building trust, working in partnership and being flexible and responsive to people's everyday realities for genuine inclusion to be achieved.
Patient Or Public Contribution: This is a co-produced project between a university, an integrated care system, two community organisations and people experiencing homelessness or being vulnerably housed. Individuals with lived experience participated as community researchers, shaping the design, methods and outcomes. Their contributions are detailed throughout the paper, which is co-authored by members of the project team, including staff from two community organisations and one community researcher.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163938 | PMC |
http://dx.doi.org/10.1111/hex.70325 | DOI Listing |
Ann Otol Rhinol Laryngol
September 2025
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Rochester, MN, USA.
Objective: To develop, implement, and evaluate a novel process used for residency application review that deemphasizes metrics known to create bias with the goal of interviewing and matching a more diverse resident cohort.
Methods: Between 2020 and 2023, a novel standardized rubric and application review process were developed and implemented at the authors' academic training program. The rubric deemphasized USMLE scores, honor society membership, and number of publications while utilizing an AI-driven pre-sort of applications, facilitating holistic review.
Open Res Eur
September 2025
Clinical trial unit, Armauer Hansen Research Institute, Addis Ababa, 1005, Ethiopia.
Background: According to the Council of International Organizations and Medical Sciences (CIOMS) 2016, post-trial access (PTA) refers to the ethical imperative that requires the sponsor, researchers, and relevant public health authority, "to make available as soon as possible any intervention or product developed, and knowledge generated, for the population or community in which the research is carried out." Law, policy, and practical guidance for PTA has so far been vague but has recently attracted and increased attention in the context of benefit sharing of scientific research results with low- and middle-income countries (LMICs).Although the number of clinical trials conducted in the Sub Saharan (SSA) countries has increased in the past two decades, plans and practices for PTA are underreported.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
An estimated 254 million people live with hepatitis B worldwide, with only 13% of people diagnosed and 3% receiving antiviral treatment. Without timely treatment, people with hepatitis B risk developing liver damage and liver cancer. In countries like Australia, where most people with hepatitis B are born in countries with higher prevalence, it is important that the knowledge and perceptions of hepatitis B in immigrant populations are explored to improve engagement in care.
View Article and Find Full Text PDFSchizophr Bull
September 2025
Department of Neurosciences, Research Group Psychiatry, Center for Clinical Psychiatry, KU Leuven, 3000 Leuven, Belgium.
Background And Hypotheses: Sexual minority youth are at increased risk for psychotic experiences, potentially due to identity-related difficulties. We hypothesized that sexual minority youth would report greater identity difficulties, and that these difficulties would be associated with heightened suspiciousness in daily life. Finally, we examined whether these associations differ between sexual minority and heterosexual adolescents.
View Article and Find Full Text PDFPublic Health Genomics
September 2025
Introduction Deliberative democracy is an inclusionary approach to reaching consensus decision-making through participative and representative engagement. The Democratizing Education for Sickle Cell Disease Gene Therapy Project used a deliberative community engagement model to partner with patient advocacy and research community members within the field of sickle cell disease (SCD) gene therapy to create new, accessible patient education materials (PEMs) about SCD gene therapy. Objective Develop PEMs for sickle cell disease gene therapy and study the process of deliberative community engaged research Methods A study of the experiences of a multi-disciplinary group of participants including patients, patient advocates, health professionals, gene therapy researchers, industry and government members using a deliberative community engagement model to develop new PEMs.
View Article and Find Full Text PDF